Lincomycin hydrochloride injection from a subsidiary of Tianjin Pharmaceutical (600488.SH) passed the generic drug consistency evaluation

Zhitongcaijing · 10/15 07:41

Zhitong Finance App News, Jinyao Pharmaceutical (600488.SH) issued an announcement. Recently, the company's subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. (hereinafter referred to as “Hubei Jinyao”) received the “Drug Supplement Application Approval Notice” for lincomycin hydrochloride injections approved and issued by the State Drug Administration, and approved the product to pass the consistent evaluation of the quality and efficacy of generic drugs.

Lincomycin hydrochloride injection is suitable for severe infections caused by sensitive strains such as streptococci, pneumococci, and staphylococci. Hubei Jinyao submitted a supplementary application for consistency evaluation of lincomycin hydrochloride injection to the Drug Evaluation Center of the State Drug Administration in December 2023 and was accepted. Up to now, Hubei Jinyao has invested a total of about 5.7 million yuan in R&D expenses in the lincomycin hydrochloride injection project.